John Didsbury is CEO of T3D Therapeutics, a startup company that is seeking money to carry a diabetes candidate into studies as a treatment for Alzheimer's disease.
A Research Triangle Park drug development startup company is looking to raise money to further studies of a drug candidate that was originally targeted as a treatment for diabetes as a treatment for Alzheimer's disease.
T3D Therapeutics CEO Dr. John Didsbury said the start-up company licensed a diabetes drug candidate from Dara BioSciences, a Raleigh-based pharmaceutical company focused on cancer supportive care products and on developing cancer treatments.
Didsbury was formerly chief scientific officer at Dara.
"It's been a personal mission of mine to identify and develop a breakthrough medicine for any disease, and this particular drug is the culmination of the search," Didsbury
said of the drug candidate, which he
believes could have multiple mechanisms for treating Alzheimer's.
"It's a tough haul, but one that just requires perseverance and tenacity."
said there are "striking similarities" between diabetes and Alzheimer's.
The company's drug candidate would work in multiple ways by regulating enzymes involved in Alzheimer's defects, he
"It acts in a myriad of ways, and like I said, it regulates the levels of certain key enzymes that are involved in the pathophysiology of the disease," he
Through T3D Therapeutics
is looking to raise money to try to carry the diabetes drug that his company licensed from Dara
into Phase 2 trials.
said the additional funding will allow the company to do some pre-clinical work, but they're still evaluating their financial strategy to figure out a way to pay for Phase 2 trials.
said company has applied for grants from the National Institutes of Health
and other organizations.